U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES  EXCHANGE ACT OF 1934

For the quarter ended:   March 31, 2000

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

          New York                                         65-0565144
-------------------------------                        -------------------
(State or other jurisdiction of                         (I.R.S. Employer
incorporation or organization)                          Identification No.)

         2018 Oak Terrace
        Sarasota, Florida                                    34231
---------------------------------------                   ----------
(Address of principal executive offices)                  (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

                                                  Name of each exchange on
      Title of each class                         which registered

               None
-----------------------------                     -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)


Copies of Communications Sent to:

                                 Mercedes Travis, Esq.
                                 Mintmire & Associates
                                 265 Sunrise Avenue, Suite 204
                                 Palm Beach, FL 33480
                                 Tel: (561) 832-5696; Fax: (561) 659-5371


<PAGE>



           Indicate by Check  whether the issuer (1) filed all reports  required
to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such  shorter  period  that the  registrant  was  required  to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days.

                       Yes    X         No
                              ---             ---

           As of March 31, 2000, there are 14,515,373  shares of voting stock of
the  registrant  issued and  outstanding  [and,  in  addition,  the  Company was
obligated to issue  50,000  shares under the  Consulting  Agreement  with Global
Development  Advisors,  Inc. on March 31, 2000, but had not issued the shares by
that date].




<PAGE>









                                     PART I

Item 1.                Financial Statements


Condensed Balance Sheets                                         F-1
Condensed Statements of Operations                               F-3
Condensed Statements of Cash Flows                               F-4
Notes to the Financial Statements                                F-6














                                       -1-

<PAGE>





<TABLE>
<CAPTION>
                          SURGICAL SAFETY PRODUCTS, INC

                            CONDENSED BALANCE SHEETS



                                             (Unaudited)
                                              March 31,                  December 31,
                                                 2000                        1999
<S>                                        <C>                      <C>
                             Assets

Current Assets
  Cash                                     $         566,812        $         516,799
  Trade receivables                                  146,554                   17,086
  Prepaid expenses and deposits                      159,862                  118,569
                                             ---------------          ---------------
    Total current assets                             873,228                  652,454
                                             ---------------          ---------------

Property and equipment, net                          189,306                  203,533
                                             ---------------          ---------------

Other Assets
  Intangible assets, net                             553,653                  270,487
  Software development costs, net                    147,152                  139,382
  Other assets                                        10,250                   10,250
                                             ---------------          ---------------
    Total other assets                               711,055                  420,119
                                             ---------------          ---------------



Total Assets                               $       1,773,589        $       1,276,106
                                             ===============          ===============
</TABLE>


                                       F-1

<PAGE>



<TABLE>
<CAPTION>
                          SURGICAL SAFETY PRODUCTS, INC

                            CONDENSED BALANCE SHEETS
                                     (cont.)

                                            (Unaudited)
                                              March 31,                December 31,
                                                   2000                    1999
<S>                                        <C>                      <C>
Liabilities and Stockholders' Equity

Current Liabilities
  Accounts payable and accrued              $        247,306        $         438,057
expenses
Line of Credit                                       100,000                  100,000
  Notes payable - related parties                     52,500                   52,500
    Total current liabilities                        399,806                  590,557

Long-Term Liabilities
   Notes payable                                   1,300,000                  650,000
    Total Liabilities                              1,699,806                1,240,557


Stockholders' Equity
  Common stock, $.001 par value,
    100,000,000 shares authorized;
   14,565,373 and 14,515,373 shares
issued and outstanding in 2000
   and 1999  respectively                             14,566                   14,516
   Common stock held in escrow                       (2,700)                  (2,700)
  Additional paid-in capital                       3,279,055                2,804,020
  Accumulated deficit                            (3,217,138)              (2,780,287)
    Total stockholders' equity                        73,783                   35,549



Total Liabilities and Stockholders'         $      1,773,589        $       1,276,106
Equity                                      -----------------       ------------------
</TABLE>










                     The accompanying notes are an integral
                       part of these financial statements.

                                       F-2

<PAGE>





<TABLE>
<CAPTION>
                          SURGICAL SAFETY PRODUCTS, INC

                       CONDENSED STATEMENTS OF OPERATIONS

                   THREE MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)

                                                             2000                        1999
                                                      -------------------          ----------------
<S>                                                  <C>                          <C>
Revenue
    Revenue                                          $            135,656         $          39,577
                                                      -------------------          ----------------

Costs and expenses
  Cost of medical products sold                                       108                       261
  Operating expenses                                              376,633                   138,984
  Research and development expenses                                14,345                     6,667
  Interest expense                                                181,421                     1,521
                                                      -------------------          ----------------
    Total costs                                                   572,507                   147,433
                                                      -------------------          ----------------

Net loss before income taxes                                    (436,851)                 (107,856)

Provision for income taxes                                               -                         -

                                                      -------------------          ----------------

Net loss                                             $          (436,851)         $       (107,856)
                                                      ===================          ================

Net loss per share                                   $            (0.038)         $         (0.010)
                                                      ===================          ================
</TABLE>









                          The accompanying notes are an
                             integral part of these
                              financial statements.

                                       F-3

<PAGE>



<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.

                       CONDENSED STATEMENTS OF CASH FLOWS

                   THREE MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)

                                                                         2000                          1999
                                                                 -------------------          --------------------
<S>                                                             <C>                          <C>
Cash Flows From Operating Activities
  Net loss                                                      $          (436,851)         $           (107,856)
  Adjustments to reconcile net loss to cash
    used in operating activities
      Depreciation and amortization                                           43,350                        29,905
      Common stock and options issued for services                            24,284                             -
      Stock option compensation expense                                                                   (91,113)
      Interest expense - issuance of convertible debt                        167,143                             -
      Decrease (increase) in operating assets
        Receivables                                                        (129,468)                      (20,634)
        Prepaid expenses and deposits                                         10,980                             -
      Increase (decrease) in operating liabilities
        Accounts payable and accrued expenses                              (190,751)                        45,570
          Total adjustments                                                 (74,462)                      (36,272)
            Net cash used in operating activities                          (511,313)                     (144,128)

Cash Flows From Investing Activities
  Furniture and equipment purchased                                          (3,056)                      (25,937)
  Software development additions                                            (15,618)                      (41,126)
    Net cash used in investing activities                                   (18,674)                      (67,063)

Cash Flows From Financing Activities
  Proceeds from related party loans                                                -                        70,000
  Repayments on line of credit, net                                                -                       100,000
  Financing and loan costs                                                  (70,000)
  Proceeds from long-term debt                                               650,000                             0
    Net cash provided by financing activities                                580,000                       170,000

Net increase (decrease) in cash                                               50,013                      (41,191)
Cash at beginning of year                                                    516,799                        41,191
Cash at end of year                                             $            566,812         $                  -
</TABLE>



                                       F-4

<PAGE>


<TABLE>
<CAPTION>
                                                                         2000                          1999
                                                                 -------------------          --------------------
<S>                                                             <C>                          <C>

Supplemental Cash Flow Information:
  Cash paid for interest                                         $            -              $         1,521
</TABLE>


For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.

Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

For the Quarter Ended March 31, 2000
-------------------------------------
- Common  stock  issued for  $52,273 of prepaid  investment  services - Deferred
financing costs of $231,385 related to the issuance of warrants in
   conjunction with issuance of notes payable.


For the Quarter Ended March 31, 1999
-------------------------------------
 -   The Company received fixed assets in the amount of $58,700 for which it had
     recorded deposits of such amount at December 31, 1998








                          The accompanying notes are an
                             integral part of these
                              financial statements.

                                       F-5

<PAGE>



Note 1 - Accounting Policies

Basis of Presentation

The condensed financial  statements of Surgical Safety Products,  Inc. (Company)
have been prepared  without audit,  pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. These consolidated financial statements should be read in
conjunction  with the financial  statements  and notes  thereto  included in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1999.

The results of  operations  for the three month  period ended March 31, 2000 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management,  the accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present  fairly the financial  positions of March 31,
2000,  the results of operations and cash flows for the three months ended March
31, 2000 and March 31, 1999, except as noted in Note 2.

Net Loss Per Share

Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) No. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents have not been included in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.

Reclassifications

Certain   reclassifications  have  been  made  in  the  prior  year's  financial
statements to conform to the current period presentation.

Note 2 - Stock Compensation Expense

During fiscal year 1998, the Company issued stock options with an exercise price
that was below  market  price to  certain  of its  employees.  Accordingly,  the
Company recorded $91,113 of compensation expense related to the issuance for the
year ended December 31, 1998.

In the first  quarter of 1999,  the Company  canceled  these  stock  options and
issued  options with an exercise  price above that of market.  Accordingly,  the
Company  decreased its payroll expense by $91,113 for the  cancellation of these
options for the quarter ended March 31, 1999.

Note 3 - Subsequent Event

                                       F-6

<PAGE>




On April 28, 2000, the investment banking firm which holds the outstanding notes
payable  converted  $102,630 of outstanding  principal and interest into 182,453
shares  of common  stock  pursuant  to the  convertible  secured  line of credit
agreement dated December 20, 1999.



                                       F-7

<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

           The  Company's  (OTC  BB:  SURG)  overall  mission  is the  research,
development, production and distribution of innovative products and services for
healthcare.   Consisting   of   both   traditional   products   and   innovative
business-to-business  e-solutions, the common goal is a safer and more efficient
environment  for  healthcare  workers,  manufacturers  and patients.  Originally
formed as a medical device company, Surgical shifted focus to being an e-company
when the Company's management recognized an untapped market niche: responding to
the critical  need for  immediate  communication  and access to  information  in
healthcare.

           Now,  the Company  operates  two  divisions  providing  products  and
services to the medical industry.  The Information  Systems Division through its
Oasis@work  product  line  provides  business-to-business  on-demand  safety and
efficiency driven e-business and information for healthcare workers. The Medical
Products and Services Division  develops,  manufactures and distributes  medical
devices.


About Oasis@work

           The Oasis@work strategy is healthcare  e-business content aggregation
and applications  integration  through a virtual private  network.  It links the
entire healthcare continuum, which includes healthcare workers,  administration,
patients, and healthcare and pharmaceutical manufacturers.  Oasis@work is a true
healthcare  data center with multiple  access  points.  It is an  Internet-based
virtual  private  network  consisting of  points-of-access  via  intranets,  the
Internet,   internet  appliances,  and  through  TouchPorts  located  throughout
healthcare  facilities  across the  country.  TouchPorts(TM)  are  user-friendly
touch-access internet appliances which allow healthcare  professionals access to
high quality clinical reference and agency mandated information services.



 Corporate Developments

           The  Company  entered  into an  agreement  with IBM  Global  Services
effective  January  3, 2000  which  includes  an IBM  Customer  Agreement  and a
Statement  of Work  (the  "IBM  Global  Agreement").  Under the terms of the IBM
Global  Agreement IBM will provide complete  implementation  and support service
solutions  for 1,200 OASiS  terminals  in an  estimated  400 end user  locations
during the 12 month period commencing December 1, 1999. On February 3, 2000, IBM
Global Services and the Company finalized the Statement of Work. The services to
be provided under the agreement include project planning, site surveys,  product
acquisition,  network design, web-site hosting services,  premises wiring, OASiS
TouchPort  Implementation,  help  desk  support  and  consulting  services.  The
estimated  cost  for  performing  the  work is  approximately  $10  million.  In
addition, IBM Global Services will bill the Company a monthly service charge for
pre and post  installation  support  services,  including 24-7 support,  and for
labor,  travel and out of pocket  expenses.  The Company will provide  technical
resources  and oversee the IBM Global's  activities.  The Company  believes that
this agreement will expedite the deployment of its OASiS systems under the terms
of its Long Term Agreement with US Surgical.

                                       -2-

<PAGE>







           In February 2000, the Company executed an Investment Banking Services
Agreement  with  Dunwoody  Brokerage  Services Inc.  d/b/a Swartz  Institutional
Finance ("Swartz"). Under the agreement, Swartz has agreed to introduce entities
to the Company for potential  strategic  partnerships,  licensing  arrangements,
mergers,  acquisitions,  investments or funding. For such services,  Swartz will
receive a scaled fee based upon the value of any completed transaction. Said fee
is payable in cash or stock at Swartz's  option and by the issuance of warrants,
the  number of which is based upon the fee  divided  by the market  price of the
Company's  Common  Stock.  There is no  obligation on the part of the Company to
accept any transaction offered by the Swartz to the Company.



           In February  2000, the Company  executed a Consulting  Agreement with
Global  Development  Advisors,  Inc.  ("GDA")).  Under the  agreement,  GDA will
provide business and marketing consulting services, assist in the implementation
of a strategic plan and assist,  coordinate  and monitor the Company's  investor
relations  program.  The  agreement  is for a term of six (6)  months and may be
extended by the Company.  In lieu of cash payments for services,  GDA has agreed
to accept 50,000 shares of the Company's  Common Stock under the Company's  2000
Stock Plan  approved by its  shareholders  on  February  28, 2000 and options to
purchase an additional 50,000 shares at an exercise price of $1.09. The issuance
was made pursuant to Section 4(2) of the Act and Rule 506.



           In December 1999, the Company  executed a Loan Agreement with Thomson
Kernaghan & Co.,  Ltd.  ("TK"),  as Agent and Lender,  whereby TK agreed to make
loans to the Company of up to $5,000,000 in installments for a period commencing
with the date of the  agreement  and ending on  November  30, 2002 (the "TK Loan
Commitment").  Under the terms of the TK Loan  Commitment,  each  installment is
supported by a convertible note and security  agreement and the Agent and Lender
are granted warrants to purchase shares of the Company's Common Stock.  Further,
2,700,000 shares are held by TK in escrow for the potential conversion under the
notes or exercise of the warrants.  Under the terms of the TK Loan Agreement, an
initial loan of $650,000  was made on December  30, 1999.  On March 31, 2000 the
Company received a second  installment  under the TK Commitment in the amount of
$650,000.  On April 28,  2000,  TK elected to convert  $100,000  of  outstanding
principal  and $2,630 of the accrued  interest  into shares of Common Stock at a
price of $0.5625 per share which represents  182,453 shares. The Company granted
TK  registration  rights and was  obligated to file a Form S-3 within sixty (60)
days of the agreement. The Company filed a registration statement on Form S-3 on
March 2, 2000 covering  initially  20,038,097  shares of its Common  Stock.  The
issuance of the  securities  was made  pursuant to  Regulation S of the Act. The
Form S-3 registration statement was declared effective on April 11, 2000.





                                       -3-

<PAGE>



           The  TK  Loan  Commitment, as  draw  downs  are taken and as interest
accrues,  will  increase  the long term debt of the  Company.  The  Company  has
entered into consulting agreements with several other potential funding sources;
however,  to date,  has not  concluded  terms for any  financing  which it feels
appropriately meets the requirements of the Company under such agreements.  With
the TK Loan Commitment and in the event additional debt is raised, it will incur
future  interest  expense.  The TK Loan  Commitment,  if fully converted and all
warrants are exercised will dilute the interest of existing  shareholders and in
the event additional equity is raised,  management may be required to dilute the
interest of existing  shareholders  further or forgo a  substantial  interest in
revenues,  if any.  In the event that the  Company  is  successful  in  securing
additional  debt  financing,  the amount of such  financing,  depending upon its
terms, would increase either the short or long term debt of the Company or both.



           On February 29, 2000, the Company  entered into a contract with Steel
Beach Productions,  Inc. ("Steel Beach") to design, develop,  implement and test
the OASiS  Version  3.0 web based  application.  The  contract is for a total of
$160,100  and is to be paid  $80,500 in cash and $80,500 in stock  options.  The
Company paid a deposit of $20,012.50 and the balance is to be paid upon delivery
of the prototype,  preliminary product and final product. The options are due at
the time of delivery of the final  product.  The common stock option number will
be calculated  based on the average  closing share price  ("ACSP") in the twenty
(20) days of trading prior to deliver of the final  product.  The exercise price
will be 50% of the twenty  (20) day average  closing  price as quoted on the OTC
BB. The number of options issued will be calculated by multiplying $80,050 times
two (2) and  dividing  by the ACSP.  The  options are to have a term of five (5)
years  and are to  conform  to  Company's  consultant  option  policy  as far as
additional  terms and  details.  This  agreement  with Steel Beach  replaces two
earlier agreements;  specifically,  one agreement for Version 2.0 dated December
30, 1999 in the amount of $37,800 in cash and $37,800 in stock options,  and one
agreement  for Version 3.0 dated  December  30, 1999 in the amount of $42,250 in
cash  and  $42,250  in stock  options.  All  efforts  expended  by  Steel  Beach
Productions under these two earlier contracts are compensated under the terms of
this  agreement.  The Company retains all propriety  rights in the  application.
Steel Beach is responsible for its own costs and expenses.  The agreement may be
canceled by either party on thirty (30) days written notice.



 Discussion and Analysis



           The  Company was  founded in 1992 to combat the  potential  spread of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.




           The  Company  was in the  development  stage until 1993 when it began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  1999,  the  Company  generated  revenues of
approximately $1,275,000 from a limited number of customers.

                                       -4-

<PAGE>



Since inception through December 31, 1999, the Company has generated  cumulative
losses of  approximately  $2,780,000.  Although  the Company has  experienced  a
significant  percentage  growth in revenues from fiscal 1992 to fiscal 1999, the
Company does not believe prior growth rates are  indicative of future  operating
results, especially in light of the contracts with US Surgical and IBM Global to
assist  in the  exploitation  of  OASiS@works.  Due to the  Company's  operating
history and limited  resources,  among other factors,  there can be no assurance
that  profitability or significant  revenues on a quarterly or annual basis will
occur  in the  future.  Moreover,  the  Company  expects  to  continue  to incur
operating  losses  through at least the first half of 2000,  and there can be no
assurance  that losses will not continue  after such date. As of the date hereof
the  Company  has  completed  installations  of fifteen  (15) units in seven (7)
hospitals.



           As discussed  in the  independent  auditors'  report,  the  operating
losses  incurred by the  Company  raise doubt about its ability to continue as a
going concern.  In addition,  with the  implementation of its agreements with US
Surgical and IBM Global and/or with the  establishment  of one or more strategic
alliances  in  addition to US Surgical  and IBM Global,  the Company  expects to
experience a period of growth,  which requires it to significantly  increase the
scale of its  operations.  This  increase  will include the hiring of additional
personnel in the areas of (i) customer service to provide  technical support for
the hospitals where  installations  are located and (ii) technical staff to make
changes requested by those hospitals.  This will result in significantly  higher
operating  expenses.  The  increase  in  operating  expenses  is  expected to be
partially funded by an increase in revenues. However, the Company's net loss may
continue  to  increase.  Expansion  of the  Company's  operations  may  cause  a
significant strain on the Company's  management,  financial and other resources.
The Company's ability to manage recent and any possible future growth, should it
occur,  will depend upon a  significant  expansion  of its sales and  marketing,
research and development,  accounting and other internal  management systems and
the  implementation  and  subsequent   improvement  of  a  variety  of  systems,
procedures and controls.  There can be no assurance that significant problems in
these areas will not occur.  Any failure to expand these areas and implement and
improve such systems,  procedures and controls in an efficient  manner at a pace
consistent with the Company's  business could have a material  adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of such expected expansion and the anticipated  increase in its operating
expenses,  as well as the difficulty in forecasting  revenue levels, the Company
expects to continue to  experience  significant  fluctuations  in its  revenues,
costs and gross margins, and therefore its results of operations.



           The  Company's  plan of  operations  for the next twelve months is to
focus on  building  revenue  from the  installation  of the OASiS  system in the
hospitals  designated by US Surgical and to install  additional OASiS systems in
hospitals not under the US Surgical agreement. Additionally, the Company intends
to install the  inservice  modules  from US Surgical and other  medical  product
manufacturers at both the US Surgical and the other hospitals.  The Company also
is aggressively seeking strategic alliances with targeted industry partners such
as manufacturers  of devices,  manufacturers  of  pharmaceuticals,  professional
organizations  such  as  nursing  associations  and  hospital  group  purchasing
organizations and integrated health networks.

                                       -5-

<PAGE>





           The  Company  estimates  that  revenues  will be  sufficient  to fund
ongoing  operations at the current level when the number of OASiS  installations
reaches  approximately  100 to 125 and the  total  number of  inservice  modules
reaches  approximately  150. The Company already has 40 inservice  modules under
the US  Surgical  agreement  and is in  discussion  with  various  manufacturers
interested in using OASiS to inservice more than 50 of their products.



           In the short term,  to fund  operations  through the first half 2000,
the Company will seek to draw upon the funds  available under the TK Commitment,
to seek additional funds from strategic  alliances with potential  clients,  its
shareholders,  from additional third party financing or seek third party debt or
equity financing other than those planned by the current anticipated agreements.
Currently,  the Company has available its existing lines of credit and has begun
hiring additional  personnel.  Provided that the TK Commitment and other funding
is available  when  needed,  the Company  believes  that it can meet its capital
needs  through  year end.  There can be no  assurance  that the Company  will be
successful in these efforts.



           As discussed in Note 10 to the Financial Statements, if the financing
referred to above is not  secured,  the  recoverability  of the  recorded  asset
amounts may be impaired.



           In 2000,  the  Company  will  require  between  $8 and $9  million in
additional capital in the form of debt or equity to fund the continued expansion
of the  OASiS  system  and its  development  to  meet  increased  demand  and to
implement  its plans for  increased  marketing of its medical  device  products.
Under the TK Commitment,  $3,700,000  remains  available  under the terms of the
agreement.  The Company has met with several venture  capital firms,  investment
bankers,  factoring companies and traditional lending sources, each of whom have
expressed  early  interest and many of whom are awaiting the  conclusion  of the
testing  period.  Other than the TK  Commitment,  the  Company  has  accepted no
definite  offer  from any  other  source.  There can be no  assurance  that such
long-term financing will be available to the Company or that it will be on terms
that the Company may seek.



Results of Operations for the Three Months Ended March 31, 2000 and 1999.



Overview



           From its inception,  the Company has incurred losses from operations.
As  of  March  31,  2000,  the  Company  had  cumulative  net  losses   totaling
approximately  $3,217,000.  During fiscal 1999,  management shifted its focus to
aggressively  marketing its proprietary  products,  especially  those associated
with OASiS@works.

                                       -6-

<PAGE>



Financial Position



           Working  capital as of March 31,  2000 was  $473,422,  as compared to
working  capital of $61,897 at December 31, 1999. This increase is primarily due
to additional borrowings on the TK Commitment.



Revenues



           For the three months  ended March 31, 2000 and 1999,  the Company had
total revenues of $135,656 and $39,577, respectively. For the three months ended
March 31, 2000,  revenues were comprised  primarily of the payments received for
Oasis unit rentals and inservice modules. The increase of $96,079 or 242% is due
to revenue from the 1999 launch of Oasis.



Selling, General, and Administrative Expenses



           For the  three  months  ended  March  31,  2000,  operating  expenses
increased by $237,649 or 171% from $138,984 for the three months ended March 31,
1999. This increase is primarily  related to marketing  support  expenditures to
sustain  the  launch of the  Company's  OASiS  system.  In  accordance  with the
Company's marketing plan for fiscal 2000,  expenses related to promotion,  trade
shows, and conventions  were increased to enhance the industry  awareness of the
company's products and services.



           In the past, the Company has focused on the design and development of
proprietary  products.  For fiscal 2000,  the Company has launched an aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical  believes that the increased  operating  expenses  incurred  during the
three  months  ended  March 31,  2000 will  position  the  Company  to  generate
increased revenue in the 2000 fiscal year.



Liquidity and Capital Resources



           The  financial  condition,  liquidity  and capital  resources  of the
Company  should be  assessed  in  context  with the  ability  of the  Company to
continue as a going concern as discussed in the independent auditors' report.



           The  Company's   operations  have  been  funded  primarily  from  the
$1,300,000  proceeds  of draw downs  under the TK  Commitment  completed  in the
fourth quarter 1999 and from cash flow

                                       -7-

<PAGE>



of  approximately   $150,000  from  licensing  fees  for  the  OASiS  units  and
partnership  fees during the nine months ended March 31, 2000.  This allowed the
Company to purchase OASiS hardware for installation,  enhance its OASiS software
and fund current operations.  At March 31, 2000, the Company has a $566,812 cash
position.



           In  addition  to the  balance of  $3,700,000  available  under the TK
Commitment,  the  Company  has a line of credit in the amount of  $100,000  that
expires in May 2017 and is  guaranteed  by Dr.  Swor.  In the past,  the line of
credit also has been used to fund operations on a short-term  basis and $100,000
is currently outstanding.



           Net cash used for investing for the three months ended March 31, 2000
was approximately  $19,000,  representing  primarily enhancements to the current
version of OASiS.


           In the short term, to fund  operations  through the balance of fiscal
2000,  the Company will be required to make  additional  draw downs under the TK
Commitment,  seek  additional  funds from  strategic  alliances  with  potential
clients,  its shareholders,  from additional third party financing or seek third
party  debt  or  equity  financing  other  than  those  planned  by the  current
agreements.  Additionally,  the Company may be required to utilize its  existing
lines of credit.  Provided  that  additional  funding is  secured,  the  Company
believes that it can meet its capital  needs  through year end.  There can be no
assurance that the Company will be successful in these efforts.



Forward-Looking Statements



           This Form 10-QSB  includes  "forward-looking  statements"  within the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities  Exchange Act of 1934, as amended.  All statements,  other
than  statements of historical  facts,  included or incorporated by reference in
this Form 10-QSB which  address  activities,  events or  developments  which the
Company expects or anticipates  will or may occur in the future,  including such
things as future capital expenditures (including the amount and nature thereof),
demand for the  Company's  products and  services,  expansion  and growth of the
Company's  business and operations,  and other such matters are  forward-looking
statements.  These statements are based on certain assumptions and analyses made
by the  Company in light of its  experience  and its  perception  of  historical
trends,  current  conditions and expected  future  developments as well as other
factors it believes  are  appropriate  in the  circumstances.  However,  whether
actual results or developments will conform with the Company's  expectations and
predictions is subject to a number of risks and uncertainties,  general economic
market and business  conditions;  the business  opportunities  (or lack thereof)
that  may be  presented  to and  pursued  by the  Company;  changes  in  laws or
regulation;  and other  factors,  most of which are  beyond  the  control of the
Company.  Consequently,  all of the forward-looking statements made in this Form
10-QSB  are  qualified  by  these  cautionary  statements  and  there  can be no
assurance  that the actual  results or  developments  anticipated by the Company
will be realized

                                       -8-

<PAGE>



or, even if substantially realized, that they will have the expected consequence
to or effects on the Company or its business or operations.



                                     PART II



Item 1.  Legal Proceedings.



           The Company knows of no legal  proceedings  to which it is a party or
to which any of its property is the subject,  which are pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.



Item 2. Changes in Securities and Use of Proceeds


           None



Item 3. Defaults in Senior Securities


           None



Item 4. Submission of Matters to a Vote of Security Holders.


           On  February  28,  2000,  the  Company  held its  annual  shareholder
meeting.  Of the 11,815373 shares  outstanding  which were qualified to vote (of
the  14,515,373  outstanding,   2,700,000  are  held  in  escrow  under  the  TK
arrangement  and were not  qualified  to vote at the  meeting),  in  attendance,
either  individually  or by proxy were holders  representing  5,960,113  shares,
which number was sufficient to form a quorum.


           At such meeting the shareholders:


          (1) approved an amendment to the Articles of Incorporation  increasing
     the number of authorized  shares of Common Stock from 20,000,000  shares to
     100,000,000 by a vote of 5,960,113 to -0-;


          (2) re-elected the Board of Directors as follows:

                                       -9-

<PAGE>



                     Dr.  Swor by a vote of 5,960,013 to 100

                     Mr.  Clark by a vote of 5,960,013 to 100

                     Mr.  Lawrence by a vote of 5,960,013 to 100

                     Mr.  Collins by a vote of 5,960,013 to 100

                     Mr.  Stuart by a vote of 5,960,013 to 100

                     Mr.  Norton by a vote of 5,960,013 to 100

                     Mr.  Swor by a vote of 5,959,253 to760, with 100 abstaining

                     Dr.  Saye by a vote of 5,960,013 to 100



Mr. Newman,  who previously was listed on the ballot,  tendered his  resignation
prior to the  shareholder  meeting and his name was withdrawn from the ballot at
the meeting;


          (3) ratified Kerkering, Barbario & Co., P.A. as the Company's auditors
     by a vote of 5,959,253 to 100 with 760 abstaining; and

          (4) approved the  Company's  2000 Stock Plan by a vote of 5,960,013 to
     100.



Item 5.  Other Information

           None



Item 6.  Exhibits and Reports on Form 8-K



     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:


<TABLE>
<S>              <C>
Exhibit No.      Description
-----------      --------------------------------------------------------------------

3.(i).1          Articles of Incorporation of Surgical Safety Products, Inc., a Florida corporation
                 filed May 15, 1992 [1]

 3.(ii).1        Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety Products, Inc. [1]

3.(ii).2         Amended Bylaws of Surgical Safety Products, Inc. [2]

10.1             Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated December 8,
                 1997 [1]
</TABLE>

                                      -10-

<PAGE>


<TABLE>
<S>              <C>
10.2             Prepaid Capital Lease Agreement with Community Health Corporation relative to
                 Sarasota Medical Hospital OASiS Installation dated January 30, 1998 [1]

10.3             Letter of Intent with United States Surgical Corporation dated February 12, 1998
                 [1]

10.4             Form of Rockford Industries, Inc. Rental Agreement and Equipment Schedule to
                 Master Lease Agreement [1]

10.5             Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6             Distribution Agreement with Morrison International Inc. dated September 30,
                 1996 [1]

10.7             Distribution Agreement with Hospital News dated August 1, 1997 [1]

10.8             Clinical Products Testing Agreement with Sarasota Memorial Hospital dated
                 January 30, 1998 [1]

10.9             Real Estate Lease for Executive Offices effective June 1, 1998 [1]

10.10            Employment Agreement with Donald K. Lawrence dated April 1, 1997 [1]

10.11            Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12            Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13            Agreement for Consulting Services with Stockstowatch.com Inc. dated March 30,
                 1988 [1]

10.14            Form of Employee Option Agreement dated July 1994 [1]

10.15            Form of Employee Option Agreement dated 1998 [1]

10.16            Form of Consultants Option Agreement dated July 1994 [1]

10.17            Form of Consultants Option Agreement dated 1998 [1]

10.18            Confidential Private Offering Memorandum dated May 30, 1995 [1]

10.19            Supplement to Private Offering Memorandum dated October 30, 1995 [1]

10.20            Stock Option Agreement with Bay Breeze Enterprises LLC dated April 9, 1998
                 [1]

10.21            Revolving Loan Agreement, Revolving Note, Security Agreement with
                 SouthTrust Bank dated May 2, 1997 [1]

10.22            Agreement between the Company and T. T. Communications, Inc. dated October
                 15, 1998 [2]

10.23            Agreement between the Company and U.S. Surgical Corporation dated October
                 28, 1998. [2]

10.24            Collaborative Agreement between the Company and Dr. William B. Saye dated
                 November 16, 1998. [2]
</TABLE>

                                      -11-

<PAGE>


<TABLE>
<S>              <C>
10.25            Kiosk Information System, Inc. Purchase Order dated November 3, 1998 [2]

10.26            Surgical Safety Products 1999 Stock Option Plan adopted January 1999 [2]

10.27            Form of the Employee Option Agreement under the Surgical Safety Products
                 1999 Stock Option Plan dated January 1999 [2]

10.28            Form of the Director, Consultant and Advisor Option Agreement under the
                 Surgical Safety Products 1999 Stock Option Plan dated January 1999 [2]

10.29            Verio, Inc. Access Service Agreement dated February 16, 1999. [2]

10.30            Form of  Investor  Subscription  Documents  and  Agreements
                 relative to the April 1999 Self Directed Private  Placement
                 Offering under Rule 506 of Regulation D.
                 [3]

10.31            Form of the Warrant issued pursuant to the April 1999 Self Directed Private
                 Placement Offering under Rule 506 of Regulation D. [3]

10.32            Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33            Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34            Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35            Private Partner Network Agreement dated July 30, 1999 with US Surgical [5]

10.36            Staff/Client Leasing Agreement dated October 16, 1999, as amended September
                 15, 1999 [5]

10.37            Agreement dated July 15, 1999 with Triton Capital Inc.[6]

10.38            Effective December 30, 1999, Loan Agreement, Note, Security Agreement,
                 Lender's Warrant, Agent's Warrant, Registration Rights Agreement and Escrow
                 Agreement relative to the December 1999 transaction with Thomson Kernaghan
                 & Co., Inc.  and Amendment thereto. [7]

10.39            Effective January 3, 2000 IBM Customer Agreement and Statement of Work. [7]

10.40            Investment Banking Services Agreement dated February 2, 2000 with Dunwoody
                 Brokerage Services Inc. [8]

10.41            Consulting Agreement dated February 15, 2000 with Global Development
                 Advisors Inc. [8]

10.42            Surgical Safety Products 2000 Stock Option and Aware Plan [8]

10.43      *     Agreement with Steel Beach Productions dated February 29, 2000.

13.1             Definitive Proxy Statement filed February 28, 2000 [8]

27.1       *     Financial Data Sheet
</TABLE>

------------------------

[1]  Previously filed with the Company's Form 10SB

                                      -12-

<PAGE>



[2]  Previously filed with the Company's Amendment No. 1 to the Form 10SB
[3]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     30, 1999
[4]  Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 1999
[5]  Previously filed with the Company's Amendment No. 2 to the Form 10SB
[6]  Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 1999
[7]  Previously filed with the Company's Form S-3 on March 2, 2000.
[8]  Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 1999.
*    Filed herewith



     (b) No Reports on Form 8-K were filed  during the  quarter  ended March 31,
2000.





                                      -13-

<PAGE>



                                   SIGNATURES



      In accordance with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this Registration  Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.



                              Surgical Safety Products, Inc. (Registrant)



Date: May 15, 2000            By:/s/ Dr.  G.  Michael Swor
                              ---------------------------------------
                               Dr.  G.  Michael Swor
                               Chief Executive Officer and Acting Chief
                               Financial Officer





                              By:/s/ Donald K. Lawrence
                              ---------------------------------------
                               Donald K. Lawrence
                               President and Chief Operating Officer





[sign page SSP 10QSB 3.31.00]





                                      -14-